T he notion that pregnancy is a time of uninterrupted joy, happiness, and contentment has been challenged by evidence-based research showing that, to the contrary, many women are distressed by depressive disorders in pregnancy. 1 Only in the past 2 decades have psychiatrists started to acknowledge and understand the morbidity and mortality associated with psychiatric disorders in the antenatal period. Although postnatal depression has acquired celebrity status, antenatal depression will need a massive campaign of equal magnitude to bring it into the limelight.
Because the signs of pregnancy closely overlap with symptoms of depression, diagnosis of antenatal depression is often difficult. Similarly, the overwhelming transition into motherhood, with its attendant anxiety, can often mask underlying pathological postpartum mental illness and delay help seeking. 2 Accurate and timely identification of perinatal depression has significant implications, both for the mother and for the developing fetus or child. In March 2007, recognizing and responding to this need, British Columbia's Ministry of Health, in partnership with the Reproductive Mental Health (RMH) program, implemented a screening initiative using the Edinburgh Postnatal Depression Scale. 3 In keeping with best-practice guidelines, this screening, which will take place between 28 to 32 weeks of gestation and 6 to 8 weeks postpartum, will positively affect the lives of pregnant and postpartum women in British Columbia.
Women are reluctant to accept any psychiatric diagnosis in pregnancy or postpartum, owing to the shock, fear, denial, and stigma that accompany mental illness. To help overcome this barrier, clinicians and women must share decision making, involve a significant other in the treatment plan, and deal with the woman's concerns compassionately. In the light of rapidly accumulating data on the adverse effects of persistent, relapsing mental illness on the mother and her child, maintaining emotional stability in the perinatal period is absolutely mandatory.
The obvious concern that arises after a diagnosis is the availability of safe, effective, and affordable intervention for the suffering mother. The treatment issue has been in the forefront of treating physicians' minds, particularly in the last 2 years, as Federal Drug Administration warnings and Health Canada advisories have been appearing almost steadily. On the one hand, research demonstrates that discontinuing medication causes relapse in about 75% of women during pregnancy. 4 On the other hand, reinstating psychotropic medications is fraught with trepidation and apprehension. Current research in relation to perinatal medication use is controversial, at best. The latest recommendation from the American College of Obstetrics and Gynecology clearly recognizes that the potential risk of continuing antidepressant use throughout pregnancy must be considered in the context of risk for relapse of depression if maintenance therapy is discontinued. 5 Given the current unease regarding the safety of antidepresdant use, many clinicians and researchers are exploring other treatment modalities in this population. Cognitive-behavioural therapy (CBT) is one such treatment that is attracting interest and consideration because of its effectiveness in the nonperinatal population. 6 piloting a project to develop a framework for applying CBT in perinatal women with mood and anxiety disorders.
This issue's In Review section includes 2 articles: the first offering an in-depth review of perinatal depression and the second focusing on the available treatment interventions in this population. Authors Shari Lusskin, Tara Pundiak, and Sally Habib 7 begin their paper poignantly with the tragic and devastating story of Andrea Yates. They review the prevalence of perinatal depression, the significance of screening for mental illness, and the reality of suicide. Their section on pathogenesis explains the fetal-programming hypothesis and the role of hormones, genetics, and stress in the etiology of this illness. They address the biological and psychosocial risk factors and cover in depth the subject of untreated perinatal depression. Finally, in their general evaluation, they guide readers to pay attention to the existence of comorbid medical and obstetrical conditions.
The second article, by Shaila Misri and Kristin Kendrick, 8 systematically reviews currently available treatment modalities in perinatal women. The paper first describes the existing research on nonpharmacologic treatments. Additionally, it discusses each class of antidepressant, outlining its efficacy as well as its adverse effects in the perinatal population. Pharmacologic treatment information is presented along with the consequences of nontreatment, which allows readers to comprehend both perspectives of the challenging and complex issue that faces treating clinicians. Research related to secretion of antidepressants in lactating women is also addressed.
Much work remains to bridge the gaps that exist in caring for the perinatal woman suffering from mental illness. On a brighter note, commitment on the part of governmental agencies to improve education, research, and clinical care for these anguished women makes this journey meaningful and worthwhile.
